Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Int J Mol Sci. 2024 Jun 1;25(11):6111. doi: 10.3390/ijms25116111.
As we move into the era of precision medicine, the growing relevance of genetic alterations to prostate cancer (PCa) development and treatment demonstrates the importance of characterizing preclinical models at the genomic level. Our study investigated the genomic characterization of eight PCa cell lines to understand which models are clinically relevant. We designed a custom AmpliSeq DNA gene panel that encompassed key molecular pathways targeting AR signaling, apoptosis, DNA damage repair, and PI3K/AKT/PTEN, in addition to tumor suppressor genes. We examined the relationship between cell line genomic alterations and therapeutic response. In addition, using DepMap's Celligner tool, we identified which preclinical models are most representative of specific prostate cancer patient populations on cBioPortal. These data will help investigators understand the genetic differences in preclinical models of PCa and determine which ones are relevant for use in their translational research.
随着精准医学时代的到来，遗传改变在前列腺癌（PCa）发展和治疗中的相关性日益增加，这表明在基因组水平上对临床前模型进行特征分析的重要性。我们的研究调查了八种 PCa 细胞系的基因组特征，以了解哪些模型具有临床相关性。我们设计了一个定制的 AmpliSeq DNA 基因面板，涵盖了针对 AR 信号、细胞凋亡、DNA 损伤修复和 PI3K/AKT/PTEN 的关键分子途径，以及肿瘤抑制基因。我们研究了细胞系基因组改变与治疗反应之间的关系。此外，我们还使用 DepMap 的 Celligner 工具，在 cBioPortal 上确定了哪些临床前模型最能代表特定的前列腺癌患者群体。这些数据将帮助研究人员了解 PCa 临床前模型中的遗传差异，并确定哪些模型与他们的转化研究相关。
